Background The effect of sodium–glucose cotransporter-2 inhibitors (SGLT2i) in patients with left ventricular assist devices (LVAD) remains uncertain. We evaluated the association between SGLT2i use and adverse outcomes during the chronic post-LVAD phase. Methods We conducted a retrospective cohort study using the TriN...
Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang et al.· Frontiers in Pharmacology· 0 citations
AIM
To evaluate whether the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) is associated with a reduced 1-year incidence of new-onset heart failure (HF) compared to statins among patients with dyslipidemia.
METHODS
We conducted a retrospective cohort study using the TriNetX global health re...
Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang et al.· QJM : monthly journal of the...· 0 citations
Background Atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis (AS) share lipid-related mechanisms. Although statins have not slowed established AS progression in randomized trials, whether proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are associated with lower incident AS risk remai...
